Last reviewed · How we verify
combination of TLC D-99 and Ifosfamide
combination of TLC D-99 and Ifosfamide is a Small molecule drug developed by Istituto Clinico Humanitas. It is currently in Phase 1 development.
At a glance
| Generic name | combination of TLC D-99 and Ifosfamide |
|---|---|
| Sponsor | Istituto Clinico Humanitas |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- combination of TLC D-99 and Ifosfamide CI brief — competitive landscape report
- combination of TLC D-99 and Ifosfamide updates RSS · CI watch RSS
- Istituto Clinico Humanitas portfolio CI
Frequently asked questions about combination of TLC D-99 and Ifosfamide
What is combination of TLC D-99 and Ifosfamide?
combination of TLC D-99 and Ifosfamide is a Small molecule drug developed by Istituto Clinico Humanitas.
Who makes combination of TLC D-99 and Ifosfamide?
combination of TLC D-99 and Ifosfamide is developed by Istituto Clinico Humanitas (see full Istituto Clinico Humanitas pipeline at /company/istituto-clinico-humanitas).
What development phase is combination of TLC D-99 and Ifosfamide in?
combination of TLC D-99 and Ifosfamide is in Phase 1.